Some consider T4N3 Stage IIIC to be a borderline case. None of these patients were included in either PACIFIC or KEYNOTE-024 for example.
Would you treat differently based on the degree of PDL1 positivity (0, 25-50%, >50%, 99%, etc.)?
Answer from: Radiation Oncologist at Academic Institution
Probably need a bit more information since T4 is fairly heterogeneous, but it is absolutely treatable. If it involves both ipsilateral lobes, then SBRT to one isolated lesion and CRT for the rest is one approach. If T4 is involved in critical mediastinal organs, probably some induction therapy with ...
Answer from: Radiation Oncologist at Community Practice
The PACIFIC study utilized Version 7 of the International Association for the Study of Lung Cancer Staging Manual, where stage IIIC lung cancer did not exist. I suspect some study participants had T4N3M0 disease.
Answer from: Medical Oncologist at Academic Institution
As Dr. @Ohri has pointed out, T4N3 in the new staging system would have included patients eligible for the PACIFIC approach, which would be the current "standard of care" for most of these patients. In those with very bulky disease where the radiation fields might be "too formidable" due to tumor vo...
Comments
Medical Oncologist at Los Angeles VA Medical Center Thank you Dr. @Corey J. Langer and Dr. @Nitin Ohri...
Medical Oncologist at Wentworth Douglass Hospital How would you approach those bulky disease patient...
Answer from: Radiation Oncologist at Community Practice
For larger tumors at high risk for local progression, I've begun treating the primary with an SBRT boost x2 a week before starting the six weeks of CRT. The benefits include increased tumor cell killing + wiping out exhausted lymphocytes and myeloid cells to allow for more active immune cell recruit...